Business Context and Reporting Period
This Form 8-K was filed by Evolent Health, Inc. on March 28, 2023. The report addresses a specific corporate event involving the termination of a material definitive agreement rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a transactional event regarding share ownership and contract termination.
Material Changes
- Termination of Lock-Up Agreement: On March 28, 2023, Evolent Health, Inc. agreed to waive all restrictions in its Lock-Up Agreement dated January 20, 2023, with Magellan Health, Inc.
- Share Sale: Magellan Health, Inc. entered into an agreement to sell its shares of Evolent Health Class A common stock to certain funds managed by a prominent institutional fund manager.
- Agreement Status: The Lock-Up Agreement will terminate concurrently with the closing of the share sale.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. The primary contingency noted is the closing of the share sale by Magellan Health, which triggers the termination of the previously disclosed Lock-Up Agreement.
Investor Verification Checklist
- Verify the closing date of the share sale by Magellan Health, Inc. to confirm the exact termination date of the Lock-Up Agreement.
- Review the January 23, 2023 Form 8-K to understand the original terms of the Lock-Up Agreement that are now being waived.
- Monitor subsequent filings for details on the identity of the institutional fund manager acquiring the shares.